Consultation for Diabetes Products
With our consultation for diabetes products we help you to enter the market successfully.
Medical products for diabetes therapy and management are an interesting market segment. They are growing at an above-average rate of 7.8 percent.
Currently, more than 387 million people worldwide suffer from diabetes. This means that the number of diabetes cases has increased more than tenfold in the past 25 years. A further increase to 592 million diabetics is expected by 2035.
In Germany, the number of diabetes cases in 2018 was about six million people. More than 90 percent suffer from type 2 diabetes, according to the report, while 300,000 to 400,000 have type 1 diabetes – 25,000 of whom are children. The number of unreported cases is particularly problematic: around 2 million people affected are unaware of their condition.
Digitization Treatment
Digitization has a major influence on medical technology progress in diabetes management. With computer support, therapy systems in diabetes treatment can be controlled more intelligently.
There will be major upheavals for diabetics due to BigData applications, e-health, mHealth, telemedicine and telemonitoring, as well as the necessary networking. There are already quite a few apps for diabetes management. Closely linked to these approaches is the vision of an international electronic patient record. Here, Germany is lagging somewhat behind in international comparison.
Diabetes apps
Diabetes is a chronic disease with a high prevalence in Germany and other Western countries. According to a WHO study, the most scientific literature has been published on diabetes in connection with mobile health compared with other diseases. For diabetics, the range of apps is the largest. For years, app developers have seen the greatest market potential in diabetes-related applications compared to other indication areas. Decisive questions for the market success of a diabetes app are, for example:
- How do diabetes apps support the patient?
- Is the diabetes app CE-marked as a medical device?
- How is the data security of the diabetes app ensured? Does the app send data to third parties, how (encrypted, unencrypted), where are the locations of the servers (Germany, Europe, USA, etc.)?
- What is the scientific and medical basis of the diabetes app? Is it recommended by professional societies or diabetes support groups?
- Do health insurance companies cover the costs of the diabetes app as part of pilot projects?
For certain diabetes apps, a new reimbursement opportunity has arisen relatively recently. Obtaining reimbursement for medical APPs in Germany, called DiGA Fast Track, is your chance for fast market access. Let sananet advise you on GiGA for diabetes apps.
Cost Savings in Diabetes Treatment
In the U.S. healthcare system, a potential cost saving of approx. 15% has been extrapolated for the treatment of diabetes through “remote health monitoring,” which could be generated predominantly in the inpatient area and in nursing care. This represents an opportunity for new innovative diabetes products that can credibly demonstrate the cost savings via a business case.
Reimbursement for Diabetes Treatment and Management
While all health insurance companies in Germany reimburse blood glucose testing with strips, innovative, non-invasive glucometers are difficult to obtain. Here, reimbursement is often only possible through individual applications.
Advice on the Market Launch of Diabetes Products
sananet advises manufacturers of diabetes monitors and products for diabetes therapy on the market launch, on the development of a trade network and on reimbursement. In marketing, this ranges from market analysis for the diabetes market to cost argumentation with the help of a business case to advice on individual case applications.
